title: Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.
abstract: High-grade undifferentiated sarcomas (HGUSs) are rare uterine malignancies arising from the endometrial stroma. They are poorly differentiated sarcomas composed of cells that do not resemble proliferative-phase endometrial stroma. High-grade undifferentiated sarcomas are characterized by aggressive behavior and poor prognosis. Cyclin D1 has been reported as a diagnostic immunomarker for high-grade endometrial stromal sarcoma with an YWHAE-FAM22 rearrangement. YWHAE-FAM22 endometrial stromal sarcomas (ESS) represent a clinically aggressive subtype of ESS classified as high-grade endometrial sarcomas, and its distinction from the usual low-grade ESS with JAZF1 rearrangement and from HGUS with no identifiable molecular aberration may be important in guiding clinical management. Median age of the patients is between 55 and 60 years. The most common symptoms are vaginal bleeding, abdominal pain, and increasing abdominal girth.Disease is usually advanced with approximately 70% of the patients staged III to IV according to the International Federation of Gynecology and Obstetrics classification. Preferential metastatic locations include peritoneum, lungs, intra-abdominal lymph nodes, and bone. Median progression-free survival ranged from 7 to 10 months, and median overall survival ranged from 11 to 23 months. There is no clear prognostic factor identified for HGUS, not even stage. The standard management for HGUS consists of total hysterectomy and bilateral salpingo-oophorectomy. Systematic lymphadenectomy is not recommended. Adjuvant therapies, such as chemotherapy and radiotherapy, have to be discussed in multidisciplinary staff meetings.
authors.affiliation: *Medical Department, Institut Gustave-Roussy, Villejuif, France (GINECO); †Division of Gynecologic Oncology, Yonsei University College of Medicine, Seoul, Korea (KGOG); ‡CHUM-Notre-Dame Hospital, Montreal, Québec, Canada (NCIC-CTG); §Peter Mac Callum, Cancer Centre, Royal Women's Hospital, University of Melbourne, Melbourne, Australia (ANZGOG); ∥Department of Gynecology and Obstetrics, IRCCS San Raffaele Hospital, Milan, Italy (MITO); ¶NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom (SGCTG); #Academic Medical Center, Amsterdam, the Netherlands (DGOG); **Beatson Oncology Centre; and Gartnavel General Hospital, Glasgow, Scotland, United Kingdom (SGCTG); ††Kliniken Essen-Mitte, Essen, Germany (AGO); and ‡‡Medical Department, Centre Léon-Bérard, Lyon, France (GINECO).
authors.forename: Patricia
authors.initials: P
authors.lastname: Pautier
authors.forename: Eun Ji
authors.initials: EJ
authors.lastname: Nam
authors.forename: Diane M
authors.initials: DM
authors.lastname: Provencher
authors.forename: Anne L
authors.initials: AL
authors.lastname: Hamilton
authors.forename: Giorgia
authors.initials: G
authors.lastname: Mangili
authors.forename: Nadeem Ahmad
authors.initials: NA
authors.lastname: Siddiqui
authors.forename: Anneke M
authors.initials: AM
authors.lastname: Westermann
authors.forename: Nicholas Simon
authors.initials: NS
authors.lastname: Reed
authors.forename: Philipp
authors.initials: P
authors.lastname: Harter
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ray-Coquard
mesh_terms: D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008495:Medical Oncology; D060787:Neoplasm Grading; D017410:Practice Guidelines as Topic; D012509:Sarcoma / Q000473:pathology* / Q000628:therapy; D012955:Societies, Medical; D014594:Uterine Neoplasms / Q000473:pathology* / Q000628:therapy